Merck Sharp & Dohme Corp. awarded $1.37B for vaccine preparation manufacturing, a significant investment in public health

Contract Overview

Contract Amount: $1,369,650,661 ($1.4B)

Contractor: Merck Sharp & Dohme Corp.

Awarding Agency: Department of Health and Human Services

Start Date: 2012-04-01

End Date: 2013-03-31

Contract Duration: 364 days

Daily Burn Rate: $3.8M/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 5

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: VACCINE FOR CHILDREN

Place of Performance

Location: WEST POINT, MONTGOMERY County, PENNSYLVANIA, 19486

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $1.37 billion to MERCK SHARP & DOHME CORP. for work described as: VACCINE FOR CHILDREN Key points: 1. The contract value represents a substantial commitment to ensuring vaccine availability. 2. Competition dynamics for this type of pharmaceutical contract can be complex, involving specialized manufacturing capabilities. 3. Potential risks include supply chain disruptions and the need for stringent quality control. 4. Performance context is critical, as vaccine efficacy and public health outcomes are directly tied to this supply. 5. This contract positions Merck within the vital pharmaceutical sector, contributing to national health security. 6. The fixed-price nature of the contract provides cost certainty for the government.

Value Assessment

Rating: good

The $1.37 billion contract awarded to Merck Sharp & Dohme Corp. for vaccine preparation manufacturing appears to be a significant investment. Benchmarking this against similar large-scale pharmaceutical procurements is challenging without more specific contract details. However, the scale suggests a critical need for the vaccine. The firm fixed-price structure offers predictability, but the ultimate value will be determined by the successful delivery and efficacy of the vaccine product.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. The presence of 5 bidders suggests a reasonably competitive environment for this specialized pharmaceutical manufacturing service. This level of competition is generally favorable for price discovery and ensuring the government receives competitive offers for essential medical supplies.

Taxpayer Impact: Full and open competition with multiple bidders helps ensure that taxpayer dollars are used efficiently by driving down costs through market forces.

Public Impact

Children across the nation benefit from the availability of this vaccine. The contract ensures the manufacturing and supply of a critical pharmaceutical product. The geographic impact is national, aiming to provide vaccine access nationwide. Workforce implications include employment in pharmaceutical manufacturing, quality control, and logistics.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases in future contract renewals.
Dependence on a single supplier for a critical vaccine could pose supply chain risks.
Ensuring consistent quality and efficacy of the manufactured vaccine is paramount.

Positive Signals

Awarded through full and open competition, suggesting competitive pricing.
Firm fixed-price contract provides cost certainty.
Significant investment indicates a high priority for public health.

Sector Analysis

The pharmaceutical preparation manufacturing sector is a critical component of the healthcare industry, characterized by high research and development costs, stringent regulatory oversight, and significant market demand. This contract falls within the broader biopharmaceutical market, which is essential for national health security. Comparable spending benchmarks would typically involve other large-scale vaccine or drug manufacturing contracts, often in the hundreds of millions to billions of dollars, depending on the product's scope and demand.

Small Business Impact

There is no explicit indication of small business set-asides for this contract. Given the specialized nature of pharmaceutical manufacturing at this scale, it is likely that larger, established firms like Merck Sharp & Dohme Corp. are best positioned to meet the requirements. Subcontracting opportunities for small businesses might exist in ancillary services such as logistics, packaging, or raw material supply, but the primary manufacturing is likely to be handled by the prime contractor.

Oversight & Accountability

Oversight for this contract would primarily fall under the Centers for Disease Control and Prevention (CDC), a division of the Department of Health and Human Services. The CDC would monitor contract performance, adherence to quality standards, and timely delivery of the vaccine preparations. Transparency is generally maintained through contract award databases, though specific performance metrics may be internal. Inspector General jurisdiction would apply in cases of fraud, waste, or abuse.

Related Government Programs

Vaccine Procurement Programs
Public Health Initiatives
Pharmaceutical Manufacturing Contracts
Centers for Disease Control and Prevention Contracts

Risk Flags

Potential for supply chain vulnerabilities.
Need for stringent quality control in pharmaceutical manufacturing.
Dependence on contractor performance for public health outcomes.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $1.37 billion to MERCK SHARP & DOHME CORP.. VACCINE FOR CHILDREN

Who is the contractor on this award?

The obligated recipient is MERCK SHARP & DOHME CORP..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).

What is the total obligated amount?

The obligated amount is $1.37 billion.

What is the period of performance?

Start: 2012-04-01. End: 2013-03-31.

What is the historical spending pattern for this specific vaccine or similar vaccine preparations by the CDC?

Analyzing historical spending for this specific vaccine or similar preparations by the CDC is crucial for understanding long-term investment trends and potential fluctuations in demand or pricing. Without access to specific historical data for this particular vaccine, we can infer that spending on essential vaccines typically remains consistent or increases over time due to factors like population growth, evolving public health recommendations, and the introduction of new vaccine formulations. Large-scale contracts like this $1.37 billion award suggest a sustained need and commitment from the government. Comparing this award to previous contracts for similar vaccines, if available, would reveal whether the current price point is in line with historical trends or represents a significant shift. Factors such as inflation, manufacturing advancements, and the number of competing bidders in prior solicitations would influence such comparisons.

How does the per-unit cost of this vaccine compare to market rates or similar government contracts?

Determining the precise per-unit cost requires knowing the total number of vaccine units procured under this $1.37 billion contract. Once that quantity is known, the per-unit cost can be calculated by dividing the total contract value by the number of units. This figure can then be benchmarked against the average selling price of the vaccine in the commercial market, as well as against per-unit costs from other government contracts for similar vaccines. Factors influencing per-unit cost include manufacturing scale, complexity of production, raw material costs, and the level of competition during the bidding process. A firm fixed-price contract aims to lock in this cost, but variations can still occur if the quantity changes or if there are significant unforeseen production issues.

What is Merck Sharp & Dohme Corp.'s track record with government vaccine contracts?

Merck Sharp & Dohme Corp. (MSD) has a long-standing and significant track record in developing, manufacturing, and supplying vaccines globally, including to government entities. They are known for producing a wide range of vaccines for various diseases. Their experience with large-scale production, navigating complex regulatory pathways (like FDA approval), and managing extensive supply chains positions them as a key player in government vaccine procurement. Past performance on similar contracts, including adherence to delivery schedules, quality control, and cost management, would be a critical factor in the government's decision-making process for awarding substantial contracts like this one. Government agencies often review past performance data when evaluating bids for major procurements.

What are the primary risks associated with this contract, and how are they being mitigated?

The primary risks associated with this large vaccine manufacturing contract include potential supply chain disruptions (affecting raw materials or distribution), manufacturing quality control failures, and the risk of the vaccine becoming less effective against evolving strains of the target disease. Mitigation strategies likely involve robust supplier vetting and diversification, stringent quality assurance protocols throughout the manufacturing process, and ongoing pharmacovigilance to monitor vaccine effectiveness and safety post-distribution. The government would also likely have contingency plans in place to address potential shortages or recalls. The firm fixed-price nature of the contract also shifts some financial risk to the contractor, incentivizing them to manage production efficiently and effectively.

How does this contract align with broader public health goals and national security objectives?

This contract directly aligns with critical public health goals by ensuring the availability of a vaccine essential for protecting a specific population, in this case, children. By securing a large supply through a substantial investment, the government demonstrates a commitment to disease prevention and population health. From a national security perspective, a healthy population is a more productive and resilient one. Furthermore, the ability to rapidly manufacture and distribute vaccines is a key component of national biodefense and pandemic preparedness, reducing vulnerability to biological threats and ensuring the continuity of essential services during health crises.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Offers Received: 5

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Merck & CO., Inc. (UEI: 054554290)

Address: 770 SUMNEYTOWN PIKE, WEST POINT, PA, 19486

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,878,630,990

Exercised Options: $3,878,630,990

Current Obligation: $1,369,650,661

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Timeline